非清髓性造血干细胞移植与持续疾病修正治疗对复发缓解型多发性硬化疾病进展的影响:一项随机临床试验
该随机临床试验纳入110例复发缓解型多发性硬化患者,随机接受非清髓性造血干细胞移植(HSCT,环磷酰胺200 mg/kg联合抗胸腺细胞球蛋白6 mg/kg)或高效或不同类别的疾病修正治疗(DMT)。主要终点为疾病进展(EDSS评分增加≥1.0分且持续至少1年,间隔6个月两次评估确认)。HSCT组3例、DMT组34例发生疾病进展,中位至进展时间DMT组为24个月,HSCT组因事件太少无法计算(HR 0.07,95%CI 0.02-0.24,P<0.001)。第一年HSCT组平均EDSS从3.38降至2.36,DMT组从3.31升至3.98(组间平均差-1.7,95%CI -2.03至-1.29,P<0.001)。无死亡,HSCT组无非造血系统4级毒性。作者认为需进一步研究重复这些发现并评估长期结局与安全性。
要点
- 复发缓解型MS患者接受非清髓性HSCT后疾病进展风险显著低于持续DMT(HR 0.07,95%CI 0.02-0.24,P<0.001)。
- HSCT组第一年平均EDSS从3.38改善至2.36,DMT组从3.31恶化至3.98,组间平均差-1.7(95%CI -2.03至-1.29)。
- DMT组中位至进展时间为24个月(IQR 18-48个月),HSCT组因事件太少无法计算。
- HSCT方案为环磷酰胺200 mg/kg联合抗胸腺细胞球蛋白6 mg/kg,无死亡,无非造血系统4级毒性。
- 作者结论:需进一步研究重复这些发现并评估长期结局与安全性。
适用人群与场景
- 复发缓解型多发性硬化患者,年龄未限定,纳入标准为过去一年接受DMT期间至少2次复发且EDSS评分2.0-6.0。
- 研究在4个美国、欧洲和南美中心进行,随机化时间为2005年9月20日至2016年7月7日。
诊断标准与关键阈值
- 疾病进展定义:EDSS评分增加≥1.0分且持续至少1年,间隔6个月两次评估确认(最小临床重要差异为0.5分)。
- EDSS评分范围0-10分(10分为最差神经 disability)。
处置流程与药物剂量
- HSCT组:非清髓性造血干细胞移植联合环磷酰胺200 mg/kg和抗胸腺细胞球蛋白6 mg/kg。
- DMT组:接受较前一年所用DMT更高效或不同类别的疾病修正治疗。
研究设计与关键结果
- 随机对照试验,110例患者随机分组(HSCT组55例,DMT组55例),73例(66%)为女性,平均年龄36岁(SD 8.6)。
- 主要终点:HSCT组3例、DMT组34例发生疾病进展;DMT组中位至进展时间24个月(IQR 18-48),HSCT组因事件太少无法计算;HR 0.07(95%CI 0.02-0.24,P<0.001)。
- 第一年EDSS变化:HSCT组从3.38降至2.36(改善),DMT组从3.31升至3.98(恶化),组间平均差-1.7(95%CI -2.03至-1.29,P<0.001)。
- 安全性:无死亡,HSCT组无非造血系统4级毒性(如心肌梗死、脓毒症或其他致残或潜在危及生命的事件)。
- 随访:103例仍在试验中,98例评估至1年,23例每年评估至5年(中位随访2年,平均2.8年)。
证据类型、等级与局限
- 证据类型:随机对照试验。
- 局限:作者指出这是初步研究,需进一步研究重复这些发现并评估长期结局与安全性。
对床旁实践的改变
- 作者认为,在复发缓解型MS患者中,与DMT相比,非清髓性HSCT延长了至疾病进展的时间。
- 作者指出需进一步研究重复这些发现并评估长期结局与安全性。
指南或共识出处
- 临床试验注册号:NCT00273364。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Hematopoietic stem cell transplantation (HSCT) represents a potentially useful approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS).
OBJECTIVE: To compare the effect of nonmyeloablative HSCT vs disease-modifying therapy (DMT) on disease progression.
DESIGN, SETTING, AND PARTICIPANTS: Between September 20, 2005, and July 7, 2016, a total of 110 patients with relapsing-remitting MS, at least 2 relapses while receiving DMT in the prior year, and an Expanded Disability Status Scale (EDSS; score range, 0-10 [10 = worst neurologic disability]) score of 2.0 to 6.0 were randomized at 4 US, European, and South American centers. Final follow-up occurred in January 2018 and database lock in February 2018.
INTERVENTIONS: Patients were randomized to receive HSCT along with cyclophosphamide (200 mg/kg) and antithymocyte globulin (6 mg/kg) (n = 55) or DMT of higher efficacy or a different class than DMT taken during the previous year (n = 55).
MAIN OUTCOMES AND MEASURES: The primary end point was disease progression, defined as an EDSS score increase after at least 1 year of 1.0 point or more (minimal clinically important difference, 0.5) on 2 evaluations 6 months apart, with differences in time to progression estimated as hazard ratios.
RESULTS: Among 110 randomized patients (73 [66%] women; mean age, 36 [SD, 8.6] years), 103 remained in the trial, with 98 evaluated at 1 year and 23 evaluated yearly for 5 years (median follow-up, 2 years; mean, 2.8 years). Disease progression occurred in 3 patients in the HSCT group and 34 patients in the DMT group. Median time to progression could not be calculated in the HSCT group because of too few events; it was 24 months (interquartile range, 18-48 months) in the DMT group (hazard ratio, 0.07; 95% CI, 0.02-0.24; P < .001). During the first year, mean EDSS scores decreased (improved) from 3.38 to 2.36 in the HSCT group and increased (worsened) from 3.31 to 3.98 in the DMT group (between-group mean difference, -1.7; 95% CI, -2.03 to -1.29; P < .001). There were no deaths and no patients who received HSCT developed nonhematopoietic grade 4 toxicities (such as myocardial infarction, sepsis, or other disabling or potential life-threatening events).
CONCLUSIONS AND RELEVANCE: In this preliminary study of patients with relapsing-remitting MS, nonmyeloablative HSCT, compared with DMT, resulted in prolonged time to disease progression. Further research is needed to replicate these findings and to assess long-term outcomes and safety.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00273364.
参考来源
- Burt RK, Balabanov R, Burman J, et al. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA. 2019. PMID: 30644983. doi:10.1001/jama.2018.18743
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。